Selected characteristics of EBV+ Hodgkin lymphoma cases, EBV− Hodgkin lymphoma cases and all controls
| Characteristic . | EBV+ HL cases (N = 40), N (%) . | EBV− HL cases (N = 88), N (%) . | Controls (N = 368), N (%) . |
|---|---|---|---|
| Age at diagnosis, y | |||
| 18-21 | 15 (37.5) | 18 (20.5) | 97 (26.4) |
| 22-25 | 10 (25.0) | 42 (47.6) | 144 (39.1) |
| 26-29 | 5 (12.5) | 10 (11.4) | 49 (13.3) |
| ≥ 30 | 10 (25.0) | 18 (20.5) | 78 (21.2) |
| Median | 24.1 | 24.7 | 24.3 |
| Interquartile range | 20.9-29.7 | 22.5-27.3 | 21.9-27.9 |
| Sex | |||
| Male | 37 (92.5) | 75 (85.2) | 327 (88.9) |
| Female | 3 (7.5) | 13 (14.8) | 41 (11.1) |
| Race | |||
| White | 32 (80.0) | 65 (73.9) | 286 (77.7) |
| Black | 6 (15.0) | 7 (7.9) | 37 (10.1) |
| Other | 2 (5.0) | 16 (18.2) | 45 (12.2) |
| Military rank at entry | |||
| Enlisted | 33 (82.5) | 75 (85.2) | 332 (90.2) |
| Officer | 4 (10.0) | 8 (9.1) | 36 (9.8) |
| Missing | 3 (7.5) | 5 (5.7) | 0 (0.0) |
| Year of first serum collection | |||
| 1988-1991 | 23 (57.5) | 52 (59.1) | 225 (61.2) |
| 1992-1994 | 12 (30.0) | 29 (33.0) | 112 (30.4) |
| 1995-1998 | 5 (12.5) | 7 (7.9) | 31 (8.4) |
| Interval between first serum collection and diagnosis date, mo | |||
| Median | 22.3 | 33.8 | 32.3 |
| Interquartile range | 11.0-37.4 | 15.0-49.9 | 14.1-51.4 |
| Histologic subtype | |||
| Nodular sclerosis | 19 (47.5) | 77 (87.5) | NA |
| Mixed cellularity | 16 (40.0) | 5 (5.7) | NA |
| Lymphocyte depletion | 1 (2.5) | 0 (0.0) | NA |
| Classic HL, not further classified | 4 (10.0) | 6 (6.8) | NA |
| Characteristic . | EBV+ HL cases (N = 40), N (%) . | EBV− HL cases (N = 88), N (%) . | Controls (N = 368), N (%) . |
|---|---|---|---|
| Age at diagnosis, y | |||
| 18-21 | 15 (37.5) | 18 (20.5) | 97 (26.4) |
| 22-25 | 10 (25.0) | 42 (47.6) | 144 (39.1) |
| 26-29 | 5 (12.5) | 10 (11.4) | 49 (13.3) |
| ≥ 30 | 10 (25.0) | 18 (20.5) | 78 (21.2) |
| Median | 24.1 | 24.7 | 24.3 |
| Interquartile range | 20.9-29.7 | 22.5-27.3 | 21.9-27.9 |
| Sex | |||
| Male | 37 (92.5) | 75 (85.2) | 327 (88.9) |
| Female | 3 (7.5) | 13 (14.8) | 41 (11.1) |
| Race | |||
| White | 32 (80.0) | 65 (73.9) | 286 (77.7) |
| Black | 6 (15.0) | 7 (7.9) | 37 (10.1) |
| Other | 2 (5.0) | 16 (18.2) | 45 (12.2) |
| Military rank at entry | |||
| Enlisted | 33 (82.5) | 75 (85.2) | 332 (90.2) |
| Officer | 4 (10.0) | 8 (9.1) | 36 (9.8) |
| Missing | 3 (7.5) | 5 (5.7) | 0 (0.0) |
| Year of first serum collection | |||
| 1988-1991 | 23 (57.5) | 52 (59.1) | 225 (61.2) |
| 1992-1994 | 12 (30.0) | 29 (33.0) | 112 (30.4) |
| 1995-1998 | 5 (12.5) | 7 (7.9) | 31 (8.4) |
| Interval between first serum collection and diagnosis date, mo | |||
| Median | 22.3 | 33.8 | 32.3 |
| Interquartile range | 11.0-37.4 | 15.0-49.9 | 14.1-51.4 |
| Histologic subtype | |||
| Nodular sclerosis | 19 (47.5) | 77 (87.5) | NA |
| Mixed cellularity | 16 (40.0) | 5 (5.7) | NA |
| Lymphocyte depletion | 1 (2.5) | 0 (0.0) | NA |
| Classic HL, not further classified | 4 (10.0) | 6 (6.8) | NA |
HL indicates Hodgkin lymphoma; and NA, not applicable.